ethnicity. 1 Disease severity depends on extent of factor deficiency and site of haemorrhage, which can range from bleeding into joints with potential for developing arthritis to fatal central nervous system bleeds.
Prophylactic intravenous administration of clotting factor concentrates is effective to prevent bleeding. Although peripheral venipuncture is generally the preferred route of administration, central venous access devices (CVADs) are frequently used to facilitate repeated or urgent treatments, particularly for small children or adults with scarred veins. 4 These devices are associated with an increased risk for infection and thrombosis. These complications not only present a burden to patients and caregivers 5 but increase the costs for care in terms of both treatments for the complication and need for reinsertion. The frequency of CVAD reinsertion or replacement can also be impacted by child growth. Reinsertion of CVADs requires costly highly skilled staff and specialized equipment for paediatric patients. 6 In addition, approximately 7%-18% of CVAD insertions result in procedural complications, such as pneumothorax, arterial puncture, haemorrhage and cardiac rhythm dysfunction. 6, 7 Once a CVAD is successfully inserted, later failure or further complications may also increase costs for care.
Recent data on the burden of illness and specific costs associated with CVADs among the paediatric haemophilia population in a realworld healthcare setting are limited. The objectives of this study were twofold: (i) to assess patient and hospital characteristics of haemophilia patients treated with and without CVADs, and (ii) to compare infection, thrombosis, length of stay (LOS), hospital costs and 30-, 60-, 90-day all-cause readmission rates between paediatric haemophilia patients with and without CVADs in a large US hospital administrative database. The hypotheses were that infections, thrombosis and readmissions would occur more frequently, LOS would be longer, and costs for index visit care would be higher among patients with versus without CVADs.
| MATERIALS AND METHODS

| Premier healthcare database
Data for this study were derived from the US Premier Healthcare
Database, which is a detailed clinical and financial database. The database contains information for more than 624 million patient encounters from over 600 geographically diverse hospitals, or one in with and without evidence of CVAD insertion during the study period.
| Study design and haemophilia population
The CVAD cohort was identified based on a search for CVADs/ports in the hospital charge master with or without ICD-9 procedure code 86.07 (insert vascular access device). The non-CVAD cohort was defined as those patients with haemophilia who had no evidence of a CVAD based on billing and ICD-9 codes during the study period.
The "index visit" for CVAD patients was defined as the first discharge that identified the CVAD during the study period, which was not necessarily the first hospital discharge for that patient in the hospital database. The index visit for non-CVAD patients was the first reported hospital encounter in the hospital database within the study timeframe. Demographic and clinical information as well as hospital characteristics for each patient was recorded from the index visit, and follow-up time was measured based on the index visit discharge date. Visit types included hospital, emergency department and nonemergency outpatient facilities.
In an effort to balance the patient demographic and clinical characteristics between the CVAD and non-CVAD treatment groups for the analyses of outcomes, haemophilia patients with CVADs were 1:1 matched to haemophilia patients without CVADs (non-CVAD control patients) using the following characteristics: age (±1 year), factor VIII therapy (yes/no) or factor IX therapy (yes/no; as defined in Table   S1 ), number of prior inpatient or outpatient encounters in previous 365 days (±5 encounters), previous hospitalization for infection in previous 365 days (yes/no), geographic area (Midwest, Northeast, West, South), inpatient visit (yes/no) and outpatient visit (yes/no). Patients with missing age, factor therapy or geographic area at the index visit were excluded prior to matching. Patients with missing or $0 costs were excluded from the cost analysis of matched patients. The outpatient cost analyses also excluded an outlying value >$100 000. Table S1 for the list of factor therapies included in the analysis). All costs were inflation-adjusted to 2014 $USD. 8 
| Study and outcome variables
| Statistical analysis
Patient and hospital characteristics were described using mean (SD) or median (IQR, range) for continuous variables and n (%) for categorical variables. To account for the correlated nature of the data, paired t test (comparing means), or Wilcoxon signed rank test (comparing medians)
for continuous variables, and McNemar's test for categorical variables were used to test for differences in characteristics between matched CVAD cases and non-CVAD controls. For the unadjusted cost comparisons in which costs were missing for a subset of patients, the Pvalues were calculated using only complete sets of matched patients.
The frequencies of infection, thrombosis and readmissions at each time point were compared for CVAD cases and non-CVAD controls using generalized estimating equation (GEE) models with binomial distribution, logit link and unstructured correlation matrix. LOS and costs were compared for the index visit using GEE models that accounted for the non-normal distribution of those outcomes with a gamma distribution, log link and unstructured correlation matrix. The frequencies of teaching status and female gender differed between CVAD cases and non-CVAD control patients (P < .05) and therefore those variables were evaluated for inclusion as covariates in the models. Only inclusion of teaching status materially changed results and improved model fit using the Quasi-Akaike Information Criterion (QIC). Hence, the final adjusted models included study group (CVAD case or non-CVAD control) and teaching status of the treating hospital. Infection, thrombosis and cost results were stratified by inpatient or outpatient index visit. Data aggregation was performed using WinSQL (Synametrics Technologies, Inc., Plainview, NJ) and statistical analysis run using SAS version 9.4
(SAS Institute, Cary, NC). Statistical significance was defined as P ≤ .05.
| RESULTS
| Patient and hospital characteristics
A total of 4793 paediatric haemophilia patients were treated at one of 548 Premier hospitals during the study period. Of these, 197 (4.1%)
had CVAD exposure, of which 155 had matched controls available in the data set (exact matches for n = 42 CVAD patients were unavailable). Therefore, the matched sample included 310 haemophilia patients (155 CVAD cases and 155 non-CVAD controls). Table 1 
visit, and most (88.7%) had <5 inpatient or outpatient encounters at the hospital in the prior year. Most patients were treated at teaching hospitals located in urban areas in the South region of the US, which is similar to the distribution of these hospital characteristics in the often had an infection in the prior year (11.3% vs 1.2%, P = .0002). Figure 1 and Table 2 Table 3 presents the results for the unadjusted total hospital LOS; as well as total hospitalization, pharmacy, and factor therapy costs for the inpatient index visits; and the total cost and pharmacy cost for the outpatient index visits. The sample sizes varied for cost analyses because all patients were not treated the same or warranted the same level of care or medications. Mean hospital LOS was greater for CVAD cases (8.8 ± 13.8) compared with controls (4.8 ± 8.6 days; P = .03). When medians were compared, LOS was significantly longer for CVAD cases compared with controls (4.5 vs 2.0 days, P = .002). As shown in Figure 2 , after adjustment for hospital teaching status, the adjusted mean LOS was 4.8 days longer for CVAD cases vs controls (9.5 vs 4.7 days, P = .002).
| All-cause infections and thrombosis
| Length of stay and associated costs
Total hospitalization, pharmacy and factor therapy medication costs for the inpatient index visit were all higher for CVAD cases, although only differences in the total hospital costs were statistically significant in adjusted models ( Figure 3A) . Adjusted mean inpatient total hospital costs were $21 811 higher ($47 200 vs $25 389, P = .02) for CVAD cases versus controls. As shown in Figure 3B , adjusted total visit and total pharmacy costs were not significantly different for CVAD cases and controls during the outpatient index visits.
| All-cause inpatient and outpatient revisits
As shown in Table 4 
| DISCUSSION
Information on the burden of illness, healthcare utilization and costs related to CVADs is limited for the paediatric haemophilia population.
This matched case-control study addressed this gap using real-world hospital data. Approximately, one-third of the paediatric haemophilia patients with CVADs were diagnosed with an infection, which was nearly double the frequency found among the non-CVAD control with CVADs experienced an infection, with an overall infection rate of 0.94 per 1000 CVAD days (interquartile range 0-1.7/1000). 13 Finally, a 1993-2000 study that examined risk factors for infection among patients with CVADs found that 24 of 59 patients (44%) reported a CVAD infection at some point during the study. 14 The frequency of infection in our study among CVAD cases (29%) was lower compared to these past studies, but this difference might be explained by international variation in infection rates for CVADs, differences in the definitions for infections, temporal trends in infection rates and/or longer follow-up for identification of infections in the prior studies. At the same time, the 17% infection estimate among controls in this study might be higher than expected in a general paediatric population, but of note is that the controls also had haemophilia, and our definition was broad and included infections that may or may not have been related to infusion of replacement factors.
Risk factors for infection include young age at time of placement and use of external CVADs. 9, 10, 13, 15, 16 Although some studies report younger age at placement as a risk factor for infections, 9, 13, 16 in our study, frequency of infections was higher among the older children.
This result is consistent with that of a nationwide Finnish study by Vepsalainen et al 10 that included 5 paediatric haemophilia treatment centres and found that young age was not associated with infection diagnosis. Information on the age at first implant or duration of catheter use for each patient was not available in our study. It is possible that the older patients in our study had longer exposure to CVADs and therefore higher risk for infectious complications. Another factor potentially contributing to infection rate is related to the type of CVAD used, which was not determined for this study. The common types of CVADs used in haemophilia patients are implantable venous access systems (ports) and external catheters. 16 Ports are most frequently used, especially in young children who are at higher risk of dislodging external CVADs. 16 One meta-analysis of 48 studies found that 77% of haemophilia patients with CVADs had fully implanted ports. 9 Thrombotic complications are well documented in other populations requiring CVADs, such as oncology patients. 16 Less is known about this complication among the haemophilia population, possibly because thrombosis is thought to be uncommon due to a relative lack of clotting factors. A meta-analysis that examined results from 19 studies and included a total of 2704 patients found only 55 (2%) reported cases of thrombosis. 9 However, studies that have prospectively followed patients and monitored for thrombosis using venograms have found that thrombosis is more common among this population than previously thought, with prevalence ranging from 18% after 33.5 months to 89% after 2 years of follow-up post-CVAD placement. [16] [17] [18] [19] [20] In one of these studies that included patients with CVADs in place for more than a year, 53% had abnormal venograms consistent with deep venous thrombosis, and all patients with a CVAD longer than 73 months had radiological evidence of thrombosis. 17 Others have also found that longer duration of the catheter use, especially beyond 4 years, 15 and young age at time of placement may increase the risk for thrombosis. 16 In the present study, frequency of diagnosed thrombosis was low (6%) among CVAD cases, as this study did not include results from screening venograms, and presence of a diagnosis code for thrombosis was only assessed at one time point and not over long-term follow-up.
Central venous access devices require meticulous care to prevent complications such as infections and thrombosis. In general, methods for the prevention of infections and thrombosis include the use of solutions or impregnated catheters with prophylactic compounds.
Examples include the use of a slush solution containing vancomycin and ciprofloxacin and heparin, 21 or treatment with prophylactic recombinant tissue plasminogen activator (r-tPA). 22 Catheters impregnated with antimicrobials have also shown to reduce incidence of infections among adults. 23 In addition, clinic policies that promote use of CVADs for as short as possible might also decrease the risk of complications. 15 Use of arteriovenous fistula may be an option when risk of complications from CVADs is high for certain patients. Although arteriovenous fistula has a low rate of complications, they are difficult in children <2 years of age, and maturation for the AFV takes approximately 8 weeks. 21, 24 This study found greater index healthcare utilization in terms of longer LOS and costs, as well as higher frequencies of outpatient and inpatient revisits for haemophilia patients with CVADs. This may reflect not just the need for more frequent factor replacement infusions or treatment for CVAD complications, but for CVAD care itself. Cost of care among haemophilia patients is high, in general, with mean annual total healthcare costs ranging from $139 102 per patient in 1995, to [25] [26] [27] Approximately, 70% of the annual care costs for haemophilia patients is attributed to factor VIII infusions. 25 As in the current study, the Haemophilia Utilization Group Study (HUGS) found that higher total annual cost of care was associated with infusing treatments through a port. 25 Specifically, the annual cost for care was 348% higher for patients receiving infusion through a port or catheter compared with patients without a CVAD (P < .01).
Healthcare budget constraints mean that more cost-effective novel treatments that reduce the duration or eliminate the need for CVADs are warranted for the haemophilia population. Novel therapies that reduce the dosing frequency of replacement therapy with clotting factors, 28 such as longer half-life products, would require less frequent administration and venous access. 29 These novel therapies may result in a reduced need for CVAD placement in a paediatric haemophilia popu- ideal to better match on the severity of disease. However, the nature of administrative data did not allow for that determination. Although we attempted to account for severity of disease by matching on factor therapy, number of previous inpatient or outpatient visits in the previous year, and previous hospitalization for infection, without inhibitor status it is difficult to ensure that the severity of the disease unrelated to the CVADs did not primarily drive differences between the groups.
Additionally, complication and cost outcomes were only examined at the index visit and may under-represent the occurrence of complications and accumulation of costs related to CVADs over long-term.
A future study that follows both the cases and controls over time in the hospital, clinic and home health nursing settings would better reflect the burden of these complications and associated costs. Finally, burden of illness or costs could not be specifically attributed to the CVAD given the administrative and observational nature of the data.
For example, no comprehensive measure of disease severity could be determined nor reasons for CVAD placement.
The main strengths of this study include the large sample of paediatric haemophilia patients from real-world hospital settings across the US and bringing together burden of illness with healthcare utilization and cost data. While matched case analysis may have limited the number of patients and power of the study, it permitted control for severity by matching on factor therapy, number of prior encounters and prior infections.
Furthermore, review of the paediatric haemophilia literature suggests that the present study is one of the larger studies available for this population.
| CONCLUSIONS
Our results highlight some important risks specific to paediatric haemophilia patients with CVADs. Specifically, we found evidence for greater frequency of infections and revisit rates for CVAD cases compared with non-CVAD matched control patients. We also found longer LOS and higher total hospital costs for the CVAD cases. The results of this study may inform further research efforts to understand the costs and benefits of novel treatment alternatives, for example prolonged half-life therapies, for young haemophilia patients requiring
CVADs. Such research efforts may provide additional insight to inform future treatment decisions.
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